Remdesivir for the treatment of COVID-19 disease: A retrospective comparative study of patients treated with and without Remdesivir

{ 'institution': [{'name': 'medRxiv'}], 'indexed': {'date-parts': [[2022, 4, 5]], 'date-time': '2022-04-05T02:59:57Z', 'timestamp': 1649127597081}, 'posted': {'date-parts': [[2021, 7, 19]]}, 'group-title': 'Infectious Diseases (except HIV/AIDS)', 'reference-count': 17, 'publisher': 'Cold Spring Harbor Laboratory', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2021, 7, 19]]}, 'abstract': '<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Remdesivir ' '(RDV) in coronavirus disease 2019 (COVID-19) has been found to be beneficial in patients with ' 'severe disease; however, its role in mild-moderate disease and its optimal timing need to be ' 'identified.</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>To assess ' 'the course of illness and final outcome in patients who received RDV at various stages of ' 'illness, and compare it to the non-RDV ' 'group.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>This is a ' 'retrospective data analysis of 1262 COVID-19 patients hospitalized from May5, 2020 to August ' '31, 2020. The primary outcomes were progression to mechanical ventilation (MV) or death. ' 'Kaplan Meier survival analysis and log rank test were used for evaluating primary ' 'outcomes.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>398 patients ' 'comprised the RDV group and 260 patients comprised the non-RDV group. ' '2/3<jats:sup>rd</jats:sup> of patients were above 50 years of age in both the groups and ' '3/4<jats:sup>th</jats:sup> patients were male. Mortality rate was 5.8% in RDV group (10.4% in ' 'non-RDV group). Mortality rate was 3.6%, 4% and 16.7% when RDV was started within 5 days, 5 ' 'to 10 days and after 10 days of symptom onset respectively. Fewer patients in RDV group ' 'progressed to MV (4.0% v/s 8.2%). Earlier discharge occurred in RDV group. Use of ' 'supplemental oxygen was observed in 44.7% patients in RDV group (54.2% in non-RDV group). No ' 'significant adverse events were observed with RDV. Survival analysis showed that probability ' 'of event (death) was significant for patients with hypertension (HT) and/or diabetes mellitus ' '(DM) in RDV ' 'group.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Early ' 'initiation of RDV is associated with shorter hospital stay, lower mortality as well as ' 'reduced need for supplemental oxygen and mechanical ventilation.</jats:p></jats:sec>', 'DOI': '10.1101/2021.07.15.21260600', 'type': 'posted-content', 'created': {'date-parts': [[2021, 7, 19]], 'date-time': '2021-07-19T21:20:20Z', 'timestamp': 1626729620000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Remdesivir for the treatment of COVID-19 disease: A retrospective comparative study of patients ' 'treated with and without Remdesivir', 'prefix': '10.1101', 'author': [ {'given': 'Surabhi', 'family': 'Madan', 'sequence': 'first', 'affiliation': []}, {'given': 'Amit', 'family': 'Patel', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kartikae', 'family': 'Sharan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shayon', 'family': 'Ghosh', 'sequence': 'additional', 'affiliation': []}, {'given': 'Vishnu', 'family': 'Venugopal', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nitesh', 'family': 'Shah', 'sequence': 'additional', 'affiliation': []}, {'given': 'Bhagyesh', 'family': 'Shah', 'sequence': 'additional', 'affiliation': []}, {'given': 'Vipul', 'family': 'Thakkar', 'sequence': 'additional', 'affiliation': []}, {'given': 'Rashmi', 'family': 'Chovatiya', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hardik', 'family': 'Shah', 'sequence': 'additional', 'affiliation': []}, {'given': 'Pradip', 'family': 'Dabhi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Minesh', 'family': 'Patel', 'sequence': 'additional', 'affiliation': []}, {'given': 'Bhowmik', 'family': 'Meghnathi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Vineet', 'family': 'Sankhla', 'sequence': 'additional', 'affiliation': []}, {'given': 'Vipul', 'family': 'Kapoor', 'sequence': 'additional', 'affiliation': []}, {'given': 'Tejas', 'family': 'Patel', 'sequence': 'additional', 'affiliation': []}, {'given': 'Maulik', 'family': 'Soni', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nirav', 'family': 'Bapat', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kaivan', 'family': 'Shah', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ritanshu', 'family': 'Chandarana', 'sequence': 'additional', 'affiliation': []}, {'given': 'Parloop', 'family': 'Bhatt', 'sequence': 'additional', 'affiliation': []}, {'given': 'Manish', 'family': 'Rana', 'sequence': 'additional', 'affiliation': []}], 'member': '246', 'reference': [ { 'key': '2021072101150660000_2021.07.15.21260600v1.1', 'unstructured': 'Weekly epidemiological update on COVID-19 - 6 July 2021, Edition 47, 6 ' 'July 2021, Emergency Situational Updates, Weekly epidemiological update ' 'on COVID-19 - 6 July 2021 (who.int)'}, { 'key': '2021072101150660000_2021.07.15.21260600v1.2', 'doi-asserted-by': 'crossref', 'unstructured': 'Cantini F , Goletti D , Petrone L et al. Immune therapy, or Antiviral ' 'Therapy, or Both for COVID-19; A systematic review. Drugs, October ' '2020.https://doi.org/10.1007/s40265-020-01421-w', 'DOI': '10.1007/s40265-020-01421-w'}, { 'key': '2021072101150660000_2021.07.15.21260600v1.3', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41422-020-0282-0'}, { 'key': '2021072101150660000_2021.07.15.21260600v1.4', 'unstructured': 'FDA’ s approval of Veklury (remdesivir) for the treatment of COVID-19 – ' 'The Science of Safety and Effectiveness. Available from: ' 'https://www.fda.gov/drugs/drug-safety-and-availability/fdas-approval-veklury-remdesivir-treatment-covid-19-science-safety-and-effectiveness'}, { 'key': '2021072101150660000_2021.07.15.21260600v1.5', 'unstructured': 'World Health Organization. Therapeutics and COVID-19: living guideline. ' 'https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.2, ' '6 July 2021, COVID-19: Clinical care'}, { 'key': '2021072101150660000_2021.07.15.21260600v1.6', 'unstructured': 'National Institutes of Health. Coronavirus Disease 2019 (COVID-19) ' 'Treatment Guidelines. https://covid19treatmentguidelines.nih.gov/ ' '(Accessed on May 27, 2021).'}, { 'key': '2021072101150660000_2021.07.15.21260600v1.7', 'unstructured': 'Infectious Diseases Society of America Guidelines on the Treatment and ' 'Management of Patients with COVID-19 ' 'https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ ' '(Accessed on February 21, 2021).'}, { 'key': '2021072101150660000_2021.07.15.21260600v1.8', 'unstructured': 'Clinical management protocol: COVID-19, Government of india ministry of ' 'health and family welfare, directorate general of health services, (emr ' 'division), version 5, 03.07.20.'}, { 'key': '2021072101150660000_2021.07.15.21260600v1.9', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2007764'}, { 'key': '2021072101150660000_2021.07.15.21260600v1.10', 'doi-asserted-by': 'crossref', 'unstructured': 'Oleander SA , Perez KK , Go AS , et al. Remdesivir for Severe ' 'Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard ' 'of Care. Clin Infect Dis 2020. Available from: ' 'https://doi.org/10.1093/cid/ciaa1041', 'DOI': '10.1093/cid/ciaa1041'}, { 'key': '2021072101150660000_2021.07.15.21260600v1.11', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.16349'}, { 'key': '2021072101150660000_2021.07.15.21260600v1.12', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)31022-9'}, { 'key': '2021072101150660000_2021.07.15.21260600v1.13', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/ofid/ofaa375'}, { 'key': '2021072101150660000_2021.07.15.21260600v1.14', 'doi-asserted-by': 'publisher', 'DOI': '10.1681/ASN.2020050589'}, { 'key': '2021072101150660000_2021.07.15.21260600v1.15', 'doi-asserted-by': 'crossref', 'first-page': '206', 'DOI': '10.1016/j.ekir.2020.10.005', 'article-title': 'Safety of Remdesivir in Patients With Acute Kidney Injury or CKD', 'volume': '6', 'year': '2021', 'journal-title': 'Kidney Int Rep'}, { 'key': '2021072101150660000_2021.07.15.21260600v1.16', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2023184'}, { 'key': '2021072101150660000_2021.07.15.21260600v1.17', 'unstructured': 'Gilead’ s Veklury® (Remdesivir) Associated With a Reduction in Mortality ' 'Rate in Hospitalized Patients With COVID-19 Across Three Analyses of ' 'Large Retrospective Real-World Data Sets. Available from: Gilead’ s ' 'Veklury® (Remdesivir) Associated With a Reduction in Mortality Rate in ' 'Hospitalized Patients With COVID-19 Across Three Analyses of Large ' 'Retrospective Real-World Data Sets | Business Wire'}], 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2021.07.15.21260600', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 7, 21]], 'date-time': '2021-07-21T08:15:51Z', 'timestamp': 1626855351000}, 'score': 1, 'resource': {'primary': {'URL': 'http://medrxiv.org/lookup/doi/10.1101/2021.07.15.21260600'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 7, 19]]}, 'references-count': 17, 'URL': 'http://dx.doi.org/10.1101/2021.07.15.21260600', 'relation': {}, 'published': {'date-parts': [[2021, 7, 19]]}, 'subtype': 'preprint'}